Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
James McAuliffeHok Fung ChanLaurine NoblecourtRamiro Andrei Ramirez-ValdezVinnycius Pereira-AlmeidaYaxuan ZhouEmily PollockFederica CappucciniIrina RedchenkoAdrian Vs HillCarol Sze Ki LeungBenoit J Van den EyndePublished in: Journal for immunotherapy of cancer (2022)
These findings highlight the synergistic potency of ChAdOx1/MVA MAGE vaccines combined with anti-PD-1 for cancer therapy, and establish the foundation for clinical translation of this approach. A clinical trial of ChadOx1/MVA MAGE-A3/NY-ESO-1 combined with anti-PD-1 will commence shortly.